Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-11-04 22:56Core Viewpoint - The major shareholder of Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. plans to reduce his shareholding due to personal financial needs, with a maximum reduction of 10,365,721 shares, representing up to 1.00% of the company's total share capital [3][4]. Shareholder Information - As of the announcement date, Mr. Yang Zongmeng holds 64,009,773 shares, accounting for 6.18% of the company's total share capital. These shares were released from restrictions on June 19, 2023 [2][3]. Reduction Plan Details - Mr. Yang plans to reduce his holdings through centralized bidding within three months after 15 trading days from the announcement date. The minimum selling price will not be lower than the adjusted price of 8.64 yuan per share, considering any corporate actions that may affect the share price [3][4][5]. - The reduction plan is consistent with previous commitments made by Mr. Yang regarding shareholding and reduction methods [5][6]. Compliance and Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's rules [6][7]. - The company and its shareholders will adhere to disclosure obligations throughout the reduction process [7].